• Immunogenicity Assessment

    • Therapeutic In Silico Services
      • ISPRIâ„¢ Website
      • ISPRI Downselectâ„¢
      • ISPRI Quantifyâ„¢
      • ISPRI Analyzeâ„¢
      • ISPRI Evaluateâ„¢
      • ISPRI-HCPâ„¢
      • ISPRI Designâ„¢
      • PANDA® Screening
    • Vaccine In Silico Services
      • iVAXâ„¢
      • EpiCCâ„¢
      • Ancer®
      • PreVAXâ„¢
    • Lab Services
      • All In Vitro Assays
      • Generic Peptide PANDA® Assays
    • Consulting Services
      • Trusted Expert Advice (TEA)
      • IRA / ISI Regulatory Writing Support
    • Why Immunogenicity Risk Assessment?
    • Why EpiVax?
  • About Us
    • Company History
    • Leadership
    • Careers
  • Press
    • News
    • Events
    • Publications
    • Blog
  • Contact Us
Use of T cell epitopes for vaccine development

Use of T cell epitopes for vaccine development

by Adam | Oct 22, 2016

Current Drug Targets – Infectious Disorders, 2001, 1, 283-293.
Immuno-informatics: Mining the genome for Vaccine Components

Immuno-informatics: Mining the genome for Vaccine Components

by Adam | Oct 22, 2016

Immunology and Cell Biology. Immunology and Cell Biology (2002) 80, 255–269.
Bioinformatics tools for identifying class I-restricted epitopes

Bioinformatics tools for identifying class I-restricted epitopes

by Adam | Oct 22, 2016

Methods (Epitope Mapping Issue). Bill Kwok, editor, Methods 29 (2003) 289–298.
Greater CD8+ TCR heterogeneity and functional flexibility in HIV-2 compared to HIV-1 infection

Greater CD8+ TCR heterogeneity and functional flexibility in HIV-2 compared to HIV-1 infection

by Adam | Oct 22, 2016

J Immunol. 2003 Jul 1; 171(1):307-16.
Mapping Cross-Clade HIV-1 Vaccine Epitopes Using a Bioinformatics Approach

Mapping Cross-Clade HIV-1 Vaccine Epitopes Using a Bioinformatics Approach

by Adam | Oct 22, 2016

Vaccine 21 (2003) 4486–4504. https://www.sciencedirect.com/science/journal/0264410X.
« Older Entries
Next Entries »

Recent Posts

  • EpiVax Announces Laboratory Expansion and Streamlined, NAM-Centric In Vitro Services    
  • Replacing Animal Models with Human-Relevant New Approach Methodologies (NAMs) for Immunogenicity in Clinic
  • EpiVax Enters its Next Chapter with SV Health Investors
  • Immunogenicity Risk Assessment Outputs to Drive a Streamlined, Risk-Based Preclinical and Clinical Strategy
  • Immunogenicity Risk Assessment Outputs to Drive a Streamlined, Risk-Based Preclinical and Clinical Strategy

Recent Comments

No comments to show.

Explore

Therapeutic In Silico Services

Vaccine In Silico Services

Lab Services

Consulting

LinkedIn

About Us

Careers

News

Events

Publications

Contact Us

This website uses cookies and similar technologies to collect information about your website experience for advertising, analytics, and other purposes as described in our Privacy Policy.